Physician profile
Daniel J Shipp
NPI 1982714853
$5,701.31
in general payments reported to CMS, 2019-2025
30 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $1,089 · 2023: $1,155 · 2024: $1,589 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,575.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.24 | 2021-2025 | |
| Novo Nordisk INC | $784.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $737.56 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.50 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $579.63 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $355.17 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $236.18 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $219.60 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $184.60 | 2022-2024 | Rexulti |
| Pfizer INC. | $103.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $89.29 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $85.22 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $79.94 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $78.71 | 2024 | |
| Abbott Laboratories | $77.89 | 2022-2023 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.20 | 2021 | |
| Sumitomo Pharma America, INC. | $48.68 | 2023-2024 | Gemtesa |
| Neurocrine Biosciences, INC. | $43.54 | 2021-2022 | |
| Dexcom, INC. | $41.54 | 2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $39.61 | 2024-2025 | Doc Band |
| Mylan Specialty L.P. | $33.78 | 2023-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $24.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.16 | 2023 | Glassia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.05 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $22.70 | 2023 | |
| Astellas Pharma US INC | $21.17 | 2023 | Veozah |
| Globus Medical, INC. | $18.77 | 2025 | Senza |
| Neos Therapeutics, LP | $16.25 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.91 | 2023 | Quviviq |
| Electromed, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.